Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046136-09
Application #
2092088
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1997-12-31
Budget Start
1996-01-01
Budget End
1996-12-31
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Kentucky
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506

  Publications

Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Mahadevan, Daruka; Unger, Joseph M; Spier, Catherine M et al. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-9
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
Gadgeel, Shirish M; Lew, Danika L; Synold, Timothy W et al. (2013) Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 72:1089-96
Nand, Sucha; Othus, Megan; Godwin, John E et al. (2013) A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 122:3432-9
von Mehren, Margaret; Rankin, Cathryn; Goldblum, John R et al. (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118:770-6
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9

Showing the most recent 10 out of 93 publications